Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04089761 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
A NA study, sponsored by Theranica.
- Terminated
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT04089761 is a NA study that was terminated before completion, run by Theranica. The registered enrollment target is 60 participants.
The verdict
NCT04089761, a NA study, was terminated before completion, sponsored by Theranica.
- TERMINATED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. This is a prospective, single arm, open label, multicenter trial of the safety and efficacy of Nerivio™ for the acute treatment of migraine in adolescents The study will be conducted in three phases: Phase I - Run-in: Phase II - Treatment phase: Phase III (optional) - Free-use
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2020-05-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04089761
The ClinicalTrials.gov registry entry for NCT04089761 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT04089761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04089761 about?
NCT04089761 is a clinical study titled "Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents". Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned p...
What is the current status of trial NCT04089761?
This trial is currently terminated. It is a NA study. The enrollment target is 60 participants. The study started on 2019-10-01. Estimated completion is 2020-05-24.
What interventions are being tested in trial NCT04089761?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT04089761?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.